

Title:

GABA neurons in the ventral tegmental area regulate non-rapid eye movement sleep in mice

Authors:

Srikanta Chowdhury^{1,2,3}, Takanori Matsubara^{1,2,3}, Toh Miyazaki^{1,2,3}, Daisuke Ono^{1,2,3},
Manabu Abe⁴, Kenji Sakimura⁴ and Akihiro Yamanaka^{1,2,3*}

Affiliations:

¹Department of Neuroscience II, Research Institute of Environmental Medicine, Nagoya University, Nagoya 464-8601, Japan

²Department of Neural Regulation, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan

³CREST, JST, Honcho Kawaguchi, Saitama 332-0012, Japan

⁴Brain Research Institute, Niigata University, Niigata 950-2181, Japan

* Correspondence should be addressed to:

Akihiro Yamanaka Ph.D.

e-mail: yamank@riem.nagoya-u.ac.jp

Tel: +81-52-789-3861

Fax: +81-52-789-3889

Abstract

The daily sleep/wakefulness cycle is regulated by coordinated interactions between sleep- and wakefulness-regulating neural circuitry. However, the detailed neural circuitry mediating sleep is far from understood. Here, we found that glutamic acid decarboxylase 67 (Gad67)-positive GABAergic neurons in the ventral tegmental area (VTA_{Gad67+}) are a key regulator of non-rapid eye movement (NREM) sleep in mice. VTA_{Gad67+} neurons project to multiple brain areas implicated in sleep/wakefulness regulation such as the lateral hypothalamus (LH) and dorsal raphe nucleus. Chemogenetic activation of VTA_{Gad67+} neurons promoted NREM sleep with higher delta power whereas optogenetic inhibition of these neurons induced prompt arousal from NREM sleep under highly somnolescent conditions, but not during REM sleep. *In vivo* fiber photometry recordings revealed that VTA_{Gad67+} neurons showed the highest population activity in NREM sleep and the lowest activity in REM sleep. Acute brain slice electrophysiology combined with optogenetics revealed that VTA_{Gad67+} neurons directly innervate and inhibit wake-promoting orexin/hypocretin neurons in the LH by releasing GABA. Taken together, we reveal that VTA_{Gad67+} neurons play a crucial role in the regulation of NREM sleep.

Keywords: VTA, NREM sleep, Gad67, chemogenetics, optogenetics, fiber photometry

Introduction

Sleep or sleep-like behavioral quiescence is known to be one of the most ubiquitously observed phenomena across the animal kingdom, from nematodes to primates (Joiner, 2016; Siegel, 2008). Broadly, sleep consists of non-rapid eye movement (NREM) sleep and REM sleep in mammals (Siegel, 2008). While the physiological functions of either NREM sleep or REM sleep, or sleep as a whole, are intriguing and shrouded in mystery, sleep deprivation in humans and experimental animals causes severe cognitive impairment (Siegel, 2008). Pioneering studies discovered certain physiological functions of sleep that include clearing metabolic waste products and toxins from the brain (Xie et al., 2013), memory encoding, consolidation and erasure (Rasch and Born, 2013), synaptic homeostasis (Bushey et al., 2011), and energy conservation (Schmidt, 2014). However, a universal function of sleep that is relevant to all animals is yet to be revealed (Joiner, 2016). As animals remain largely isolated from sensory processing and goal-oriented activity during sleep, it is expected that the regulation of sleep, both NREM and REM, as well as arousal should be controlled by the central nervous system. Many brain areas and residing cellular subtypes have been shown to be critical in regulating sleep-wakefulness. For instance, orexin/hypocretin-producing neurons (orexin neurons) in the lateral hypothalamus (LH) project to and activate monoaminergic, cholinergic, and other peptidergic neurons as well as other orexin neurons to induce and maintain wakefulness (Brown et al., 2012; Inutsuka and Yamanaka, 2013; Sakurai, 2007; Scammell et al., 2017). Subsequently, these monoamine neurons inhibit sleep-active γ -aminobutyric acid (GABA)-ergic neurons in the ventrolateral preoptic area (VLPO) in the hypothalamus to induce wakefulness (Saito et al., 2018; Saper et al., 2010). It is reported that some wake-active neurons also display activity during REM sleep (Brown et al., 2012; Scammell et al., 2017). Comparatively, NREM sleep is regulated by neurons that release classical fast neurotransmitters, including GABA. For example, circadian rhythms and/or homeostatic sleep pressures activate GABAergic neurons in the VLPO and median preoptic nucleus (MnPO), which in turn inhibit wake-promoting orexin/hypocretin, monoaminergic, and cholinergic systems (Scammell et al., 2017). While this flip-flop switch model of sleep-wake regulation is well established, recent studies have demonstrated a critical involvement of other brain areas and neuronal subtypes in regulating the

transformations and subsequent maintenance of specific vigilances states (Liu et al., 2017; Oishi et al., 2017b).

Reinforcement learning, motivation, and locomotion, as well as the adaptation of responses to salient stimuli, all of which demand behavioral arousal, are critically regulated by a midbrain structure called the ventral tegmental area (VTA) in both rodents and primates (Arsenault et al., 2014; Fields et al., 2007). While one could also expect a critical role for VTA in the regulation of sleep/wakefulness, it is only recently that VTA dopamine (DA) neurons have been reported to have a fundamental role in the maintenance of the awake state as well as in the consolidation of arousal in mice (Eban-Rothschild et al., 2016; Oishi et al., 2017a). However, the VTA contains considerable heterogeneity among the neuronal subtypes, which include GABAergic and glutamatergic neurons alongside DA neurons. Studies have reported that about 60–65% of VTA neurons are dopaminergic, whereas 30–35% are GABAergic, and 2–3% are glutamatergic neurons (Nair-Roberts et al., 2008; Pignatelli and Bonci, 2015).

As GABAergic neurons provide strong inhibition to the wake- and REM-active DA neurons in the VTA (Eban-Rothschild et al., 2016; Tan et al., 2012; van Zessen et al., 2012), it is probable that these GABAergic neurons in the VTA may also participate in sleep/wakefulness regulation. Moreover, GABA-mediated responses have been implicated in the modulation of the sleep/wakefulness cycle (Brown et al., 2012; Scammell et al., 2017). However, no study has been conducted to date to confirm the roles of GABAergic neurons in the VTA in the regulation of sleep/wakefulness. Therefore, we examined the role of glutamic acid decarboxylase 67 (Gad67)-positive neurons in the VTA on sleep/wakefulness by using AAV-aided whole-brain anterograde tracing, neural manipulations by chemo- and optogenetics, fiber photometry, as well as slice electrophysiology. Gad67 is an isomer of an enzyme that synthesizes GABA from glutamic acid, suggesting that Gad67+ neurons are GABAergic neurons (Erlander et al., 1991). We revealed that Gad67+ neurons in the VTA (VTA_{Gad67+}) are highly active during NREM sleep and send their axons to multiple brain areas that were previously reported to regulate sleep/wakefulness. Bidirectional manipulations of neuronal activity and fiber photometry recordings of VTA_{Gad67+} neurons revealed that these neurons are active in NREM sleep and promote NREM sleep. Part of the NREM sleep-promoting effect of VTA_{Gad67+} neurons might be mediated through inhibition of wake-promoting orexin/hypocretin neurons.

Results

GABAergic neurons in the VTA project to brain areas involved in the regulation of sleep/wakefulness

Glutamatergic, GABAergic, and dopaminergic (DA) neurons are intermingled in the VTA. Here, we focused on the GABAergic neurons and tried to identify relevant projection areas. To specifically target GABAergic neurons in the VTA (VTA_{GABA}), *Gad67-Cre* mice (Higo et al., 2009) were unilaterally injected with a Cre-inducible AAV virus carrying humanized renilla green fluorescent protein (hrGFP) (Figure 1a). Many hrGFP-positive neurons were observed in the VTA (Figure 1b-d). These hrGFP-positive neurons were *Gad67*-positive but tyrosine hydroxylase-negative (TH, an enzyme and marker of DA neurons in the VTA) (Figure 1b, n = 4 mice) confirming that these hrGFP-positive neurons were GABAergic. Within the VTA, we counted a total of 636 ± 122 neurons per animal (n = 4 mice). Among them, $63.5 \pm 1.8\%$ were TH-positive neurons (DA neurons) and $36.1 \pm 1.8\%$ were hrGFP-positive neurons. Only $0.4 \pm 0.1\%$ were co-labeled with hrGFP and TH (Figure 1c). hrGFP was distributed not only in the soma, but also in the axons. We could even anterogradely trace axons to reveal projection sites since hrGFP emits a strong fluorescence (Figure 1d-f). Along with local innervations, we found long-range projections of *Gad67*⁺ neurons in the VTA (VTA_{Gad67+}) throughout the brain. Among these sites, the lateral hypothalamus (LH) and the central nucleus of the amygdala (CeA) were densely innervated (Figure 1e-f). Moderate projections were found in the nucleus accumbens (NAc), ventral pallidum (VP), parafascicular thalamic nucleus (PF), periaqueductal grey (PAG), ventral nucleus of the lateral lemniscus (VLL), dorsal raphe nucleus (DR), and pontine reticular nucleus (PnO). These brain areas are also reported to be involved in the modulation of the sleep/wakefulness, suggesting that VTA_{Gad67+} neurons might play a role in this regulation (Brown et al., 2012).

Chemogenetic activation of VTA_{Gad67+} neurons induced NREM sleep with high delta power

Next, to reveal whether VTA_{Gad67+} neurons contribute to the regulation of sleep/wakefulness, we activated these neurons by means of pharmacogenetics (chemogenetics), using designer receptors exclusively activated by designer drugs (DREADD). We bilaterally injected a Cre-inducible AAV virus to express either hM3Dq-mCherry or mCherry into the VTA of *Gad67-Cre* mice (Figure 2a-b,

Supplemental Figure 1a-b). We then confirmed the function of hM3Dq by applying its ligand clozapine-N-oxide (CNO) to acute brain slices while recording neuronal activity (Supplemental Figure 1c). As expected, CNO application significantly increased the firing frequency of hM3Dq-expressing, but not mCherry-expressing, VTA_{Gad67+} neurons (Supplemental Figure 1d-e, hM3Dq: $286 \pm 61\%$, $n = 8$ cells; mCherry: $110 \pm 8\%$, $n = 6$ cells, $p = 0.02$, unpaired t -test). Next, to analyze the effect of CNO-induced activation of VTA_{Gad67+} neurons in sleep/wakefulness states, electroencephalogram (EEG) and electromyogram (EMG) electrodes were implanted in *Gad67-Cre* mice (Figure 2a). After recovery from the surgery and behavioral habituation (see methods), either saline or CNO (1 mg/kg) were administered intraperitoneally (i.p.) just before the onset of the dark period (at 8 pm). CNO administration resulted in a significantly reduced time spent in wakefulness and increased time spent in NREM sleep (also known as slow-wave sleep) in the hM3Dq-mCherry expressing mice, but not in mCherry-expressing mice (Figure 2c-d, hM3Dq: $n = 6$ mice, mCherry: $n = 4$ mice). The CNO-induced increase in NREM sleep lasted for at least 4 hours after CNO administration (Figure 2d, % change from saline in hM3Dq-mCherry-expressing mice: wakefulness 22 ± 2 , NREM 259 ± 18 , REM 30 ± 8 , vs saline NREM, $p = 3.0e-4$, paired t -test). Interestingly, the delta power (1-5 Hz) during NREM sleep was significantly increased in the CNO-injected group compared to the NREM sleep in the saline-injected control group (mean relative delta power for 4 hr post-injection: hM3Dq-saline: $83 \pm 3\%$, hM3Dq-CNO: $138 \pm 8\%$, $p = 0.001$, paired t -test), suggesting that VTA_{Gad67+} neurons might be a critical regulator of slow wave in NREM sleep (Figure 2e-g). However, time spent in REM sleep remained unaffected during activation of VTA_{Gad67+} neurons, suggesting that VTA_{Gad67+} neurons are involved in the regulation of NREM sleep, but not REM sleep (Figure 2c-d).

Optogenetic inhibition of VTA_{Gad67+} neurons induced wakefulness

Since activation of VTA_{Gad67+} neurons resulted in increases in NREM sleep with increases in delta wave power, we next examined the selective inhibition of VTA_{Gad67+} neurons, which might be expected to increase wakefulness. To test this, we used an acute inhibition strategy with optogenetics. An inhibitory anion channel, channelrhodopsin 2 (ACR2), was expressed in VTA_{Gad67+} neurons (Figure 3a and Supplementary Figure 2a-b) (Mohammad et al., 2017). We first confirmed the function of ACR2 employing *in vitro* electrophysiology. Three weeks after injection of AAV

(expressing either ACR2-2A-mCherry or mCherry) into the VTA of *Gad67-Cre* mice, we prepared acute brain slices including the VTA and performed cell-attached recordings from mCherry-expressing neurons. Blue light (6.8 mW/mm^2) was able to completely silence the spontaneous activity of ACR2-2A-mCherry-expressing $\text{VTA}_{\text{Gad67}+}$ neurons ($n = 10$ cells), whereas light irradiation on mCherry alone-expressing neurons had no such effect ($n = 7$ cells) (Supplementary Figure 2d-f). Next, using these two groups of mice, we implanted fiber optics at a diameter of $400 \text{ }\mu\text{m}$ into the VTA along with EEG and EMG recordings (Figure 3a and 3b). After recovery and habituation, continuous blue light for 5 sec was illuminated every 15 min for 24 hr (Figure 3c). Interestingly, blue light illumination immediately induced wakefulness from NREM sleep, but not from REM sleep, in mice expressing ACR2-2A-mCherry ($n = 6$ mice, Figure 3d-f). No such effect was observed in mice expressing mCherry alone ($n = 5$ mice). However, as the light-induced influences on NREM sleep and wakefulness showed an extended effect after the cessation of light (Figure 3d-e), with behaviors taking around 60 sec to return to the basal state, we sought to identify whether optogenetic inhibition of $\text{VTA}_{\text{Gad67}+}$ neurons also causes prolonged wakefulness. We, therefore, isolated the trials depending on sleep-wakefulness states just before light illumination in the cases of wakefulness, NREM, or REM sleep (with the same state lasting ≥ 30 sec before light illumination). Surprisingly, we found that optogenetic inhibition of $\text{VTA}_{\text{Gad67}+}$ neurons in the state of wakefulness prolonged the time spent in wakefulness in all sorted trials compared to behavior of the control group (Figure 3f, ACR2: $35 \pm 5 \text{ s}$, mCherry: $8 \pm 8 \text{ s}$; $p = 0.02$, unpaired *t*-test). Again, REM sleep was not affected. Therefore, these data showed that *in vivo* optogenetic inhibition of $\text{VTA}_{\text{Gad67}+}$ neurons promoted and sustained wakefulness in mice. This result clearly suggested that $\text{VTA}_{\text{Gad67}+}$ neurons have a role in the regulation of not only NREM sleep but also wakefulness.

Next, we tested whether brief (5 sec) optogenetic inhibition of $\text{VTA}_{\text{Gad67}+}$ neurons can induce arousal even under conditions of high homeostatic sleep pressure. To test this, mice were sleep deprived for 4 hr, starting at light onset, and were then allowed to experience recovery sleep for 30 min (Figure 4a). Sleep-deprived animals usually display extended NREM sleep because of high homeostatic sleep pressure. Moreover, the slow-wave activity in NREM sleep increases during recovery sleep (Lancel et al., 1992). However, to our surprise, even under such a higher sleep pressure condition, optogenetic inhibition of $\text{VTA}_{\text{Gad67}+}$ neurons could successfully and

immediately induce wakefulness in all trials (Figure 4b and 4c). Once again, induced-wakefulness displayed an extended effect after cessation of light, whereby it took 54 ± 14 sec to return to NREM sleep. Taken together, these results suggest that VTA_{Gad67+} neurons might be involved in the initiation and maintenance of physiological NREM sleep.

VTA_{Gad67+} neurons showed the highest population activity during NREM sleep

Our chemogenetic activation and optogenetic inhibition studies suggest that the *in vivo* activity of VTA_{Gad67+} neurons might change across brain states with putatively higher activity during NREM sleep. To test this hypothesis, we recorded the population activity of VTA_{Gad67+} neurons using fiber photometry (Inutsuka et al., 2016). A Cre-inducible AAV expressing the fluorescent calcium indicator GCaMP6f (Chen et al., 2013) was unilaterally injected into the VTA of *Gad67-Cre* mice ($n = 8$ mice; Figure 5a and Supplemental Figure 3a). First, we tested whether GCaMP6f signal from VTA_{Gad67+} neurons correspond to firing frequency *in vitro* (Supplemental Figure 3b). The fluorescence intensity from GCaMP6f was increased in an evoked firing frequency-dependent manner ($n = 13$; Supplemental Figure 3c-e, $\Delta F/F$ (%), normalized to 100 Hz), 10 Hz: 9.2 ± 3.0 , 20 Hz: 23.0 ± 5.4 , 50 Hz: 52.1 ± 6.2). Next, activity recordings were performed *in vivo* by a fiber optic inserted into the VTA area (Supplemental Figure 4b). Offline determination of vigilance states was aided by signals from EEG-EMG electrodes (Figure 5a-b). Both fluorescence and EEG-EMG were recorded during the light period in the home cage after habituation. We observed robust changes in the fluorescence signal across brain states (Figure 5c, Supplemental Figure 3f). To facilitate the statistical analyses of mean $\Delta F/F$ among vigilance states, we compared the fluorescence signal at the transition of vigilance states. We found that VTA_{Gad67+} neurons show the highest population activity during NREM and the lowest during REM sleep (Figure 5d, Supplemental Figure 3f). Notably, VTA_{Gad67+} neurons began to increase their activity before wake-to-NREM transitions (mean $\Delta F/F$: Wake: $2.9 \pm 0.4\%$, NREM: $3.8 \pm 0.4\%$, $p = 2.5e-6$) and decrease their activity before NREM-to-REM (mean $\Delta F/F$: NREM: $5.0 \pm 0.5\%$, REM: $2.7 \pm 0.3\%$, $p = 2.4e-5$) and NREM-to-wake (mean $\Delta F/F$: NREM: $3.8 \pm 0.5\%$, wake: $3.0 \pm 0.4\%$, $p = 2.4e-4$) transitions. However, the changes in signal from REM-to-wake (mean $\Delta F/F$: REM: $2.9 \pm 0.4\%$, wake: $3.7 \pm 0.5\%$, $p = 0.02$) was comparatively less significant and occurred only

after the onset of state transition. Most interestingly, the population activity of VTA_{Gad67+} neurons was found to be completely contrary to DA neuronal activity in the VTA (Dahan et al., 2007; Eban-Rothschild et al., 2016), further suggesting that Gad67+ neurons and DA neurons differentially modulate sleep-wakefulness in mice (Eban-Rothschild et al., 2016).

VTA_{Gad67+} neurons directly inhibited wake-promoting orexin neurons in the lateral hypothalamus

Dense projections were observed from VTA_{Gad67+} neurons to a well-known sleep-wake regulatory brain region, the lateral hypothalamus (LH), where wake-active and wake-promoting orexin (LH_{orexin}) neurons are exclusively located. Thus, we wondered whether VTA_{Gad67+} neurons mediate their sleep-promoting effect through the inhibition of LH_{orexin} neurons. To test this, we generated a bigenic *orexin-Flippase (Flp); Gad67-Cre* mouse, in which orexin neurons exclusively express Flp recombinase and Gad67+ neurons express Cre recombinase (Figure 6a-c) (Chowdhury et al., *Manuscript submitted*). We injected a Cre-inducible AAV expressing the blue light-gated cation channel channelrhodopsin2 (E123T/T159C; ChR2) (Berndt et al., 2011) in the VTA as well as a Flp-inducible AAV expressing tdTomato in the LH of *orexin-Flp; Gad67-Cre* mice (Figure 6 a-c). In slice recordings from VTA_{Gad67+} neurons expressing ChR2, blue light flashes (6.8 mW/mm²) through an objective lens could depolarize and significantly increase spontaneous firing frequency to approximately 650% compared with before light illumination (Figure 6d-f, n = 5 cells, *p* = 0.004 vs either pre or post, one-way ANOVA followed by post-hoc Tukey). Next, we recorded spontaneous firings from tdTomato-positive neurons (orexin neurons) in the LH by loose cell-attached recordings and the nerve terminals of VTA_{Gad67+} neurons in the LH were activated by illuminating blue light pulses (Figure 6g and supplementary Figure 5a). We found that blue light inhibited LH_{orexin} neuron firing in a light-pulse frequency-dependent manner (5, 10 and 20 Hz). However, no such effect was observed when yellow light pulses (20 Hz) were applied (Berndt et al., 2011) (Figure 6h and Supplementary Figure 5b-c).

To reveal the mechanism of inhibition of orexin neurons, we performed additional electrophysiological experiments. We performed whole-cell voltage clamp recordings from orexin neurons at -60 mV holding potential (mV_{hold}) to record post-synaptic currents. Activation of nerve terminals of VTA_{Gad67+} neurons in the LH

(blue light pulse, duration of 5 ms) induced a post-synaptic current (PSC) in 8 out of 11 cells. These light-induced PSCs were blocked by gabazine (10 μ M), a GABA_A receptor antagonist (Figure 7a-c, aCSF: -253 ± 70 pA, gabazine: -9 ± 3 pA, $n = 8$, $p = 1.6e-10$, paired t -test). This result suggests that GABA is involved in generating the light-induced PSCs in LH_{orexin} neurons. The average synaptic delay from light onset was recorded as 6.2 ± 1.0 ms (Figure 7d). To rule out the effect of glutamate, we blocked both AMPA (α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and NMDA (N-Methyl-D-aspartic acid) type glutamate receptors by applying CNQX (20 μ M) and AP5 (50 μ M), respectively, in the extracellular bath solution. CNQX and AP5 could not block light-induced PSCs, while the combination of CNQX, AP5, and gabazine could inhibit (Figure 7e-g, AP5+CNQX: -188 ± 38 pA, with gabazine: -6 ± 2 pA, $n = 7$, $p = 3.1e-9$). Again, a delay of 6.7 ± 0.3 ms was found (Figure 7h). Finally, to confirm whether light-induced PSCs were indeed driven by monosynaptic release of GABA from VTA_{Gad67+} neurons, we performed an additional set of experiments (Figure 7i-l). We found that tetrodotoxin (TTX, 1 μ M), a blocker of voltage-gated sodium channels, inhibited the light-induced PSCs (Figure 7i-k, aCSF: -340 ± 73 pA, TTX: -2 ± 0.6 pA, $n = 6$). However, combined application of TTX along with 4-AP (4-aminopyridine, 1 mM), a voltage-gated potassium (Kv) channel blocker, could rescue the light-induced PSCs, suggesting a monosynaptic connection between VTA_{Gad67+} neurons and LH_{orexin} neurons (-291 ± 131 pA). Again, the rescued current was blocked by adding gabazine (-6 ± 2 pA), but not by CNQX (-295 ± 121 pA). Finally, to further confirm that Cl⁻ channels are involved in this GABAergic input, we changed mV_{hold} to +90 mV. The calculated the reversal potential of Cl⁻ under recording conditions were near 0 mV (2.2 mV). As expected, we found that the current direction of light-induced PSCs was opposite at +90 mV_{hold} (Figure 7j-k, 237 ± 115 pA). All these experiments confirm that LH_{orexin} neurons were directly innervated and inhibited by VTA_{Gad67+} neurons.

Discussion

By employing anterograde tracing and localization of brain-wide neural projections, bidirectional neuronal manipulations, fiber photometry, slice electrophysiology, as well as sleep recordings, we provide multiple lines of evidence in favor of our claim that VTA_{Gad67+} neurons regulate NREM sleep in mice. GABAergic neurons constitute a significant part of the VTA (Nair-Roberts et al., 2008; Pignatelli and Bonci, 2015) and help to regulate the function of DA neurons residing nearby (Tan et al., 2012; van Zessen et al., 2012). Dysregulation of signaling pathways in the VTA is associated with drug abuse and several other psychiatric disorders including schizophrenia, bipolar disorder, and major depressive disorder (Winton-Brown et al., 2014; Wulff et al., 2010). Moreover, irregular sleep-wake timing and architectures are recognized as common co-morbidities in many neuropsychiatric and neurodegenerative diseases (Wulff et al., 2010). Therefore, the relationship between neurochemical signaling in the VTA and the regulation of sleep/wakefulness poses an interesting point of study. However, classical lesioning experiments suggest that cats with reduced dopamine levels exhibit decreased behavioral arousal but no significant change in electro-cortical waking (Jones et al., 1973). It is only very recently that investigators have shown an interest in understanding the role of the VTA in the regulation of sleep/wakefulness (Eban-Rothschild et al., 2016; Oishi et al., 2017a; Yang et al., 2018). However, not much scientific literature has been published focusing on the functional importance of GABAergic neurons in the VTA. Therefore, our findings on the role of these neurons in sleep/wakefulness regulation will provide a conceptual and systematic framework for the association between sleep and psychiatric disorders and will generate opportunities to study VTA-related dysregulation in mental disorders.

van Zassen and colleagues reported that *in vivo* optogenetic activation of GABAergic neurons in the VTA in mice disrupts reward consummatory behavior (van Zessen et al., 2012). In addition, Shank *et al.* reported that dose- and time-related selective ablation of GABAergic neurons in the VTA in rats increased spontaneous locomotor activity (Shank et al., 2007). These studies are consistent with the hypothesis that GABAergic neurons in the VTA play an important role in the regulation of behavior. We now argue that one reason for such disruption in behavior might be promotion of NREM sleep by selective activation of GABAergic neurons in the VTA.

Using bidirectional chemogenetic manipulations as well as neurotoxic lesions in rats, a recent study found that neurons in the rostromedial tegmental nucleus (RMTg), also known as the GABAergic tail of the VTA, are essential for physiological NREM sleep (Yang et al., 2018). Although Yang *et al.* did not identify neuronal subtypes involved in the RMTg, their results might be related to our findings. Interestingly, VTA_{Gad67+} neurons in our study are located throughout the VTA, but at a somewhat higher density toward the caudal parts of the VTA. More recently, Takata *et al.* reported that GABA neurons in the ventral medial midbrain/pons, which includes the VTA region, regulate sleep/wake cycles by modulating DA neurons (Takata et al., 2018). These GABA neurons should include VTA_{Gad67+} neurons. Indeed, GABAergic neurons regulating NREM sleep might be distributed across both VTA and RMTg.

Chemogenetic activation of VTA_{Gad67+} neurons induced NREM sleep accompanied by higher delta power (slow wave) compared with control conditions (Figure 2g), suggesting that VTA_{Gad67+} neurons might play a critical role in the generation of slow wave in NREM sleep. Recently, Oishi *et al.* reported that activation of either the cell bodies of GABAergic neurons in the core of NAc or their axonal terminals in the VP enabled evoked slow wave sleep (Oishi et al., 2017b). In addition, activation of GABAergic neurons in the basal forebrain, which includes the VP, produced wakefulness, whereas their inhibition induced sleep (Anaclet et al., 2015). These facts suggest that inhibition of GABAergic neurons in the VP is a critical pathway to generate slow wave in NREM sleep. We also found that VTA_{Gad67+} neurons moderately project to the VP. Therefore, we reasoned that VTA_{Gad67+} neurons projecting to the VP might be involved in the generation of slow wave sleep.

Population activity recordings across vigilance states shows that DA neurons in the VTA exhibit higher activity in REM sleep versus either wake or NREM sleep (Eban-Rothschild et al., 2016). On the contrary, VTA_{Gad67+} neurons exhibit a completely opposite activity pattern from that of DA neurons across vigilance states, with highest activity during NREM sleep (Figure 5). This suggests an existing functional interaction between DA neurons and VTA_{Gad67+} neurons. Using *in vivo* single unit recordings in rats, Lee *et al.* found wake- and REM-active VTA_{GABA} neurons, suggesting that there might be several types of VTA_{GABA} neurons (Lee et al., 2001). Our fiber photometry data showed that VTA_{Gad67+} neurons exhibit weak activity even during wakefulness. This might suggest that VTA_{Gad67+} neurons are also comprised of several subtypes. However,

most VTA_{Gad67+} neurons are predominantly active in NREM sleep. Therefore, additional research is needed to clarify any electrophysiological, anatomical, and/or functional variations of GABAergic neurons in the VTA. Very recently, Yu et al. reported that coordinated interaction between GABA and glutamate neurons in the VTA regulate sleep/wakefulness in mice (Yu et al., 2019). Although this study similarly found the NREM-sleep promoting role of VTA_{GABA} neurons, the *in vivo* activity of VTA_{GABA} neurons are quite contrast from us with the highest activity observed during wake and REM sleep. Difference was that Yu et al. used *VGAT-Cre* mice and we used *Gad67-Cre* mice to target GABAergic neurons. Again this difference might suggest the existence of different type of GABAergic neurons in the VTA.

Optogenetic inhibition of VTA_{Gad67+} neurons induced immediate wakefulness from NREM sleep, but not from REM sleep, suggesting the importance of uninterrupted neuronal activity of VTA_{Gad67+} neurons for the maintenance of NREM sleep. Both chemogenetic activation and optogenetic inhibition data suggest that VTA_{Gad67+} neurons might not play a decisive role in the physiological regulation of REM sleep. Interestingly, inhibition of VTA_{Gad67+} neurons prolonged wakefulness (Figure 3f). This result might suggest that VTA_{Gad67+} neurons also regulate levels of wakefulness. This is consistent with data showing that VTA_{Gad67+} neurons displayed weak activity in wakefulness in terms of population activity. This idea is also supported by observed increases in spontaneous locomotor activity following selective ablation of VTA_{GABA} neurons in rats (Shank et al., 2007). These facts might suggest that an improvement in alertness and ability to maintain wakefulness require the suppression of activity of VTA_{GABA} neurons.

One possible cellular mechanism underlying NREM sleep promotion by VTA_{GABA} neurons is via inhibition of DA neurons residing in the VTA. In addition to this, our results showed that direct inhibition of wake-promoting LH_{orexin} neurons might contribute to the induction of NREM sleep. Projection-specific activation of VTA_{GABA} neuron nerve terminals using optogenetics will reveal the most responsible pathways to induce NREM sleep. It will also be fascinating to study how VTA_{GABA} neurons are regulated. Using an optimized trans-synaptic retrograde tracing approach, Faget and colleagues recently labeled afferent neurons to DA, GABA, or glutamate neurons in the VTA and found that these populations receive qualitatively similar inputs, with dominant and comparable projections from three brain areas known to be critical for sleep/wakefulness regulation: LH, raphe, and ventral pallidum (Faget et al., 2016). Here

1 we report that VTA_{Gad67+} neurons project to those areas, suggesting the existence of a
2 mutual interaction with these brain areas to regulate sleep/wakefulness.

3 In conclusion, our study elucidated that VTA_{GABA} neurons regulate NREM
4 sleep in mice. These neurons might be a possible target for therapeutic intervention in
5 treating sleep-related disorders as well as neuropsychiatric disorders.

Funding: This work was supported by JST CREST (JPMJCR1656 to A.Y.), KAKENHI grants (18H02523, 18KK0223, 18H05124 and 16H01271 to A.Y., and 18H02477 to D.O.) from MEXT Japan, and by SUZUKEN MEMORIAL FOUNDATION to A.Y.

Acknowledgments: We thank C. J. Hung for supporting the sleep data analysis, S. Kikuchi for performing the sleep deprivation study and supporting the creation of movies, G. Wang for analyzing the separation of vigilance state transitions, S. M. Rahman for assisting cell counting procedures, and S. Tsukamoto and Y. Miyoshi for other technical assistance.

Author contributions: S.C. and A.Y. designed the experiments. S.C. performed optogenetic, fiber photometry, and electrophysiology studies and analyzed the data, T.Ma. performed AAV injections and the brain-wide anterograde tracing study, T.Mi. performed the chemogenetic study and analyzed data, D.O. contributed to animal surgery for the fiber photometry study and supported the optogenetic study and data analysis, and M.A. and K.S. generated *orexin-flippase* and *Gad67-Cre* mice. A.Y. supervised the project. S.C. and A.Y. wrote the manuscript with input from the other co-authors.

Financial disclosure statements: None

Methods

Animals

All experimental protocols that involved animals were approved by the Institutional Animal Care and Use Committees, Research Institute of Environmental Medicine, Nagoya University, Japan. All efforts were made to reduce the number of animals used and also to minimize the suffering and pain of animals. Animals were maintained on a 12-hour light-dark cycle (lights were turned on at 8:00 am), with free access to food and water.

Generation and Microinjection of Adeno-Associated Virus (AAV) Vectors

AAV vectors were produced using the AAV Helper-Free System (Agilent Technologies, Inc., Santa Clara, CA). The virus purification method was adopted from a previously published protocol (Inutsuka et al., 2016). Briefly, HEK293 cells were transfected together with three distinct plasmids carrying a pAAV vector, pHelper and pAAV-RC (serotype 9 or DJ; purchased from Cell Biolabs Inc., San Diego, CA) using a standard calcium phosphate method. HEK293 cells were collected and suspended in artificial CSF (aCSF) solution (in mM: 124 NaCl, 3 KCl, 26 NaHCO₃, 2 CaCl₂, 1 MgSO₄, 1.25 KH₂PO₄ and 10 glucose) three days post-transfection. Following multiple freeze-thaw cycles, the cell lysates were treated with benzonase nuclease (Merck, Darmstadt, Germany) at 37°C for 30 min, and were centrifuged 2 times at 16,000 g for 10 min at 4°C. The supernatant was used as the virus-containing solution. Quantitative PCR was performed to measure the titer of purified virus. Virus aliquots were then stored at -80°C until use.

Adult *Gad67-Cre* or *orexin-Flp*; *Gad67-Cre* mice of both sexes were subjected to either unilateral or bilateral injection of AAV(9)-CMV-FLEX-hrGFP (100 X1 nl, 6.0×10¹² copies/ml), AAV(9)-CAG-FLEX-hM3Dq-mCherry (200 X2 nl, 1.1×10¹² copies/ml), AAV(9)-CMV-FLEX-ACR2-2A-mCherry (300 X2 nl, 6.2×10¹² copies/ml), AAV(9)-CAG-FLEX-mCherry (300 X2 nl, 1.9×10¹² copies/ml), AAV(9)-CMV-FLEX-ChR2 (ET/TC)-eYFP (300 nl, 3.0×10¹³ copies/ml), or AAV(9)-CMV-FLEX-GCaMP6f (300 X1 nl, 1.3×10¹² copies/ml) into the VTA (3.0 to 3.7 mm posterior and 0.4 to 0.6 mm lateral from bregma, 4.0 to 4.2 mm deep from brain surface) under ~1.2% isoflurane (Fujifilm Wako Pure Chemical Industries, Osaka, Japan) anesthesia. *Orexin-Flp*; *Gad67-Cre* bigenic mice also received bilateral injection of AAV(DJ)-CMV-dFrt-tdTomato-WPRE (300 X2 nl, 8.1×10¹² copies/ml) into the lateral hypothalamic area (1.5 mm posterior and 0.5 mm lateral from bregma, 5.0 mm deep from brain surface), which were used for slice electrophysiological experiments.

Immunohistochemistry

Under deep anesthesia with 0.65% pentobarbital sodium solution (Kyoritsu Seiyaku Corporation, Tokyo, Japan) diluted with saline (1.0 ml/kg body weight), mice were subjected to serial transcardial perfusion first using ice-cold saline (20 ml) and then

ice-cold 4% formaldehyde solution (20 ml, Fujifilm Wako Pure Chemical Industries, Ltd., Osaka, Japan). The brain was then gently collected and post-fixed with 4% formaldehyde solution at 4°C overnight. Later, the brain was subsequently immersed in phosphate-buffered saline (PBS) containing 30% sucrose at 4°C for at least 2 days. Coronal sections of either 40 or 80 µm thickness were made using a cryostat (Leica CM3050 S; Leica Microsystems, Wetzlar, Germany; or Leica VT1000 S, Wetzlar, Germany), and slices were preserved in PBS containing 0.02% of NaN₃ at 4°C until stained. For staining, coronal brain sections were immersed in blocking buffer (1% BSA and 0.25% Triton-X in PBS), and then incubated with primary antibodies (TH: Millipore, Massachusetts, 1/1000 dilution; DAT: Frontier Institute Co. Ltd., Hokkaido, Japan, 1/1000 dilution, Japan; DsRED: Santa Cruz Biotechnology, Heidelberg, Germany, 1/1000 dilution; GFP: Fujifilm Wako Pure Chemical Corporation, Osaka, Japan, 1/1000 dilution; orexin-A: Santa Cruz Biotechnology, 1/1000 dilution) at 4°C overnight. For Gad67 staining, slices were incubated with anti-Gad67 antibody (Millipore, 1/500 dilution in blocking buffer without Triton-X) at 4°C for 4 days. After washing by blocking buffer three times, the brain sections were then incubated with secondary antibodies for 1 hr at room temperature. After washing with the same blocking solution three times, slices were stained by 4',6-diamidino-2-phenylindole dihydrochloride (DAPI: Thermo Fisher Scientific, Yokohama, Japan) across several experiments. Slices were mounted in 50% glycerol solution and examined with an epifluorescence microscope (BZ-9000, Keyence, Osaka, Japan or IX71, Olympus, Tokyo, Japan).

Anterograde Tracing and Localization of Brain-Wide Neural Projections

A Cre-inducible AAV carrying the hrGFP gene (AAV(9)-CMV-FLEX-hrGFP; 100 X1 nl, 6.0×10¹² copies/ml) was unilaterally injected into the VTA of *Gad67-Cre* mice. Three weeks post-injection, animals were perfused-fixed and brain slices of 80 µm thickness were made serially from the anterior to the posterior part of the brain using a vibratome (Leica VT1000 S, Wetzlar, Germany). After DAPI staining, slices were serially mounted and images were taken using an epifluorescence microscope (BZ-9000, Keyence, Osaka, Japan or IX71, Olympus, Tokyo, Japan). Images were taken using an identical configuration in the microscope and were then analyzed using ImageJ (US National Institute of Health) software. Projection scorings were made in all visible projection sites, except for the VTA, by first selecting the most innervated brain region and comparing other areas to that region.

Surgery for EEG-EMG and/or Optogenetics, Fiber Photometry

Procedures for implanting EEG and EMG electrodes for polysomnographic recording experiments were adapted from the previously published protocol (Tabuchi et al., 2014). Briefly, virus-injected mice were implanted with EEG and EMG electrodes under isoflurane anesthesia. Immediately after surgery, each mouse received an i.p. injection of 10 ml/kg of an analgesic solution containing 0.5 mg/ml of Carprofen (Zoetis Inc.,

Parsippany-Troy Hills, NJ). Mice were singly housed for 7 days during the recovery period. Mice were then connected to a cable in order to allow them to move freely in the cage as well as to be habituated to the recording cable for another 7 days.

For fiber-guided optogenetic experiments, virus-injected mice received a surgical implantation of single fiber optic cannula (400 μ m; Lucir Inc., Japan), along with EEG-EMG electrodes, above the VTA (AP -3.3 to -3.6 mm; ML 0.4 to 0.6 mm; DV -3.75 mm. For fiber photometry experiments, virus-injected mice received surgical implantation of a single guide cannula (400 μ m; Thorlabs Inc.) just above the VTA (AP -3.3 mm; ML 0.4 to 0.5 mm; DV -4.0 mm) to target VTA^{Gad67+} neurons. These mice were also implanted with the EEG-EMG electrodes following the protocol described above.

Vigilance State Determination

EEG and EMG signals were amplified (AB-610J, Nihon Kodan, Japan), filtered (EEG at 1.5-30 Hz, and EMG at 15-300 Hz), digitized (at a sampling rate of 128 Hz), and recorded (Vital Recorder, Kissei Comtec Co., Ltd, Japan) from individual habituated mice. Recorded signals were then analyzed to identify vigilance states using SleepSign (Kissei Comtec) software. Vigilance state identification was assisted by an infrared sensor as well as by video monitoring through a CCD video camera (Amaki Electric Co., Ltd., Japan) during both the light and dark periods (Kissei Comtec). Video recording during the dark period was aided by infrared photography (Amaki Electric Co., Ltd., Japan). EEG and EMG data were automatically scored in epochs (every 4 sec) and classified as wake, rapid eye movement sleep, or non-rapid eye movement sleep. All auto-screened data were examined visually and corrected. The EEG analysis yielded power spectra profiles over a 0~20 Hz window with 1 Hz resolution for delta (1-5 Hz), theta (6-10 Hz), alpha (11-15 Hz), and beta (16-20 Hz) bandwidths. The criteria for determining vigilance states were the same as the protocol described elsewhere (Tabuchi et al., 2014): briefly, (i) wake (low EEG amplitude with high EMG or locomotion score), (ii) NREM sleep (low EMG and high EEG delta amplitude), and (iii) REM sleep (low EMG as well as low EEG amplitude with high theta activity, and should be followed by NREM).

In Vivo Recordings and Data Analysis of Neuronal Activity Using Fiber Photometry

In vivo population activity of the VTA^{Gad67+} neurons was recorded using a silica fiber of 400 μ m by implanting the fiber just above the VTA. Details of the fiber photometric recordings are described elsewhere (Inutsuka et al., 2016). Briefly, the fiber photometry system (COME2-FTR/OPT, Lucir, Tsukuba, Japan) utilizes a custom-made single silica fiber of 400 μ m diameter to deliver excitation light and to detect fluorescence from GCaMP6f, simultaneously. Blue excitation light (465 nm, 0.5 mW at the tip of the silica fiber) was produced by a high-power LED system (PlexonBright OPT/LED Blue_TT_FC, Plexon, Dallas, TX). The LED-emitted excitation light was reflected by a dichroic mirror and coupled to the silica fiber (400 μ m diameter) through an excitation bandpass filter

(path 472 ± 35 nm). GCaMP6f-emitted green fluorescence was collected by the same silica fiber passed through a bandpass emission filter (path 525 ± 25 nm) and guided to a photomultiplier (PMTH-S1M1-CR131, Zolix instruments, Beijing, China). The fiber photometry signal was recorded by Vital Recorder (Kissei Comtec Co., Ltd, Japan) along with the EEG/EMG signals. Fiber photometry signals were collected at a sampling frequency of 128 Hz and the software averaged every 10 samples to minimize fluctuations and noise.

After recording and sleep analysis, the fiber photometry signal was outputted along with the EEG and EMG signals as a text file of raw data. For each experiment, the photometry signals at all data points were motion averaged and were then converted to $\Delta F/F$ by $\Delta F/F(t) = (F(t) - F_{\min})/F_{\min}$. We recorded the signals in the light period as nocturnal animal mice usually show multiple transitions among different vigilance states during the light period. All mice were subjected to at least two recording sessions with at least a 2-day interval in between each session to allow photobleaching recovery. We separated all sleep-state transitions that last at least for 1 min before and after the state change. All the sessions were selected after the photometry signal became stable, as we observed a decay of photometry signal at the beginning of the recordings.

Acute Brain Slice Preparation

Preparation of acute brain slices and subsequent electrophysiological recordings were performed as previously reported with a slight modification (Chowdhury and Yamanaka, 2016). Briefly, mice were decapitated under isoflurane (Fujifilm Wako Pure Chemical Industries) anesthesia and the brain was quickly isolated and chilled in an ice-cold cutting solution (in mM: 110 K-gluconate, 15 KCl, 0.05 EGTA, 5 HEPES, 26.2 NaHCO₃, 25 glucose, 3.3 MgCl₂ and 0.0015 (\pm)-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid) gassed with 95% O₂ and 5% CO₂. Coronal slices of 300 μ m thickness containing either VTA or LH were prepared using a vibratome (VT-1200S; Leica, Wetzlar, Germany) and were temporarily placed in an incubation chamber containing a bath solution (in mM: 124 NaCl, 3 KCl, 2 MgCl₂, 2 CaCl₂, 1.23 NaH₂PO₄, 26 NaHCO₃ and 25 glucose) gassed with 95% O₂ and 5% CO₂ in a 35°C water bath for 30-60 min. Slices were then incubated at room temperature in the same incubation chamber for another 30-60 min for recovery.

In Vitro Electrophysiology

After the recovery period, acute brain slices were transferred to a recording chamber (RC-26G; Warner Instruments, Hamden, CT). The recording chamber was equipped with an upright fluorescence microscope (BX51WI; Olympus, Tokyo, Japan) stage and was superfused with a 95% O₂ and 5% CO₂-gassed bath solution at a rate of 1.5 ml/min using a peristaltic pump (Dynamax; Rainin, Oakland, CA). An infrared camera (C3077-78; Hamamatsu Photonics, Hamamatsu, Japan) was installed in the fluorescence microscope along with an electron multiplying charge-coupled device

camera (Evolve 512 delta; Photometrics, Tucson, AZ) and both images were separately displayed on monitors. Micropipettes of 4-6 MΩ resistance were prepared from borosilicate glass capillaries (GC150-10; Harvard Apparatus, Cambridge, MA) using a horizontal puller (P-1000; Sutter Instrument, Novato, CA). Patch pipettes were filled with KCl-based internal solution (in mM: 145 KCl, 1 MgCl₂, 10 HEPES, 1.1 EGTA, 2-Mg-ATP, 0.5 Na₂-GTP; pH 7.3 with KOH) with osmolality between 280–290 mOsm. Electrophysiological properties of cells were monitored using an Axopatch 200B amplifier (Axon Instrument, Molecular Devices, Sunnyvale, CA). Output signals were low-pass filtered at 5 kHz and digitized at a sampling rate of 10 kHz. Patch clamp data were recorded through an analog-to-digital (AD) converter (Digidata 1550A; Molecular Devices) using pClamp 10.2 software (Molecular Devices). Voltage clamp recordings were performed at a holding potential of -60 mV, unless otherwise stated. Blue light at a wavelength of 475 ± 18 nm and yellow light at a wavelength of 575 ± 13 nm were generated by a light source that used a light-emitting diode (Spectra Light Engine; Lumencor, Beaverton, OR) and guided to the microscope stage with a 1 cm diameter optical fiber. Brain slices were illuminated through the objective lens of the fluorescence microscope.

In vitro calcium imaging

Gad67+ neurons were identified by green fluorescence of GCaMP6f. Excitation light of 475 ± 18 nm (6.8 mW/mm²) was emitted into the brain slice containing VTA through the objective lens of a fluorescence microscope. The light source (Spectra light engine) was controlled by the Metamorph software (Molecular Devices). GCaMP6f fluorescence intensity was recorded continuously using the Metamorph software at a rate of 1 Hz with 100 msec of exposure time. To synchronize the calcium imaging and patch clamp recording, pClamp software was triggered by the TTL output from Metamorph software. Metamorph data were analyzed by setting the region of interest (ROI) on GCaMP6f expressing VTA_{Gad67+} neurons and the ΔF/F was calculated from the average intensity of the ROI. Finally, ΔF/F values for 10, 20 and 50 Hz were normalized to the ΔF/F values for corresponding 100 Hz frequencies.

Data Analysis and Presentation

Immunostaining data were analyzed and processed with ImageJ (US National Institute of Health) and BZ-X Analyzer (Keyence BZ-X710 microscope). Electrophysiological analysis was performed with either Clampfit10 (Molecular Devices, Sunnyvale, CA) or Minianalysis software (Synaptosoft Inc., Decatur, GA). Analysis of EEG-EMG data was performed using SleepSign software (Kissei Comtec) and data were outputted as text files. Further analyses were performed using Microsoft Excel. Electrophysiological data were saved as American Standard Code for Information Interchange (ASCII) files and further data calculations were performed in Microsoft Excel. Graphs were generated in Origin 2017 (OriginLab, Northampton, MA) using data from Excel. Statistical analysis

- 1 was also performed with Origin 2017. Graphs were generated using Canvas 15 (ACD
- 2 Systems, Seattle, WA).

References

- 1 Anaclet, C., Pedersen, N.P., Ferrari, L.L., Venner, A., Bass, C.E., Arrigoni, E., and Fuller,
2 P.M. (2015). Basal forebrain control of wakefulness and cortical rhythms. *Nature*
3 *communications* 6, 8744.
- 4 Arsenault, J.T., Rima, S., Stemmann, H., and Vanduffel, W. (2014). Role of the primate
5 ventral tegmental area in reinforcement and motivation. *Curr Biol* 24, 1347-1353.
- 6 Berndt, A., Schoenenberger, P., Mattis, J., Tye, K.M., Deisseroth, K., Hegemann, P., and
7 Oertner, T.G. (2011). High-efficiency channelrhodopsins for fast neuronal stimulation at
8 low light levels. *Proceedings of the National Academy of Sciences of the United States*
9 *of America* 108, 7595-7600.
- 10 Brown, R.E., Basheer, R., McKenna, J.T., Strecker, R.E., and McCarley, R.W. (2012).
11 Control of sleep and wakefulness. *Physiol Rev* 92, 1087-1187.
- 12 Bushey, D., Tononi, G., and Cirelli, C. (2011). Sleep and Synaptic Homeostasis:
13 Structural Evidence in *Drosophila*. *Science* 332, 1576.
- 14 Chen, T.-W., Wardill, T.J., Sun, Y., Pulver, S.R., Renninger, S.L., Baohan, A., Schreiter,
15 E.R., Kerr, R.A., Orger, M.B., Jayaraman, V., *et al.* (2013). Ultrasensitive fluorescent
16 proteins for imaging neuronal activity. *Nature* 499, 295.
- 17 Chowdhury, S., and Yamanaka, A. (2016). Optogenetic activation of serotonergic
18 terminals facilitates GABAergic inhibitory input to orexin/hypocretin neurons. *Scientific*
19 *reports* 6, 36039.
- 20 Dahan, L., Astier, B., Vautrelle, N., Urbain, N., Kocsis, B., and Chouvet, G. (2007).
21 Prominent burst firing of dopaminergic neurons in the ventral tegmental area during
22 paradoxical sleep. *Neuropsychopharmacology : official publication of the American*
23 *College of Neuropsychopharmacology* 32, 1232-1241.
- 24 Eban-Rothschild, A., Rothschild, G., Giardino, W.J., Jones, J.R., and de Lecea, L.
25 (2016). VTA dopaminergic neurons regulate ethologically relevant sleep–wake
26 behaviors. *Nature Neuroscience* 19, 1356.
- 27 Erlander, M.G., Tillakaratne, N.J., Feldblum, S., Patel, N., and Tobin, A.J. (1991). Two
28 genes encode distinct glutamate decarboxylases. *Neuron* 7, 91-100.
- 29 Faget, L., Osakada, F., Duan, J., Ressler, R., Johnson, A.B., Proudfoot, J.A., Yoo, J.H.,
30 Callaway, E.M., and Hnasko, T.S. (2016). Afferent Inputs to Neurotransmitter-Defined
31 Cell Types in the Ventral Tegmental Area. *Cell Rep* 15, 2796-2808.
- 32 Fields, H.L., Hjelmstad, G.O., Margolis, E.B., and Nicola, S.M. (2007). Ventral

Tegmental Area Neurons in Learned Appetitive Behavior and Positive Reinforcement. Annual Review of Neuroscience 30, 289-316.

Higo, S., Akashi, K., Sakimura, K., and Tamamaki, N. (2009). Subtypes of GABAergic neurons project axons in the neocortex. Front Neuroanat 3, 25.

Inutsuka, A., and Yamanaka, A. (2013). The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions. Frontiers in endocrinology 4, 18-18.

Inutsuka, A., Yamashita, A., Chowdhury, S., Nakai, J., Ohkura, M., Taguchi, T., and Yamanaka, A. (2016). The integrative role of orexin/hypocretin neurons in nociceptive perception and analgesic regulation. Scientific reports 6, 29480.

Joiner, W.J. (2016). Unraveling the Evolutionary Determinants of Sleep. Curr Biol 26, R1073-r1087.

Jones, B.E., Bobillier, P., Pin, C., and Jouvet, M. (1973). The effect of lesions of catecholamine-containing neurons upon monoamine content of the brain and EEG and behavioral waking in the cat. Brain Research 58, 157-177.

Lancel, M., van Riezen, H., and Glatt, A. (1992). Enhanced slow-wave activity within NREM sleep in the cortical and subcortical EEG of the cat after sleep deprivation. Sleep 15, 102-118.

Lee, R.S., Steffensen, S.C., and Henriksen, S.J. (2001). Discharge profiles of ventral tegmental area GABA neurons during movement, anesthesia, and the sleep-wake cycle. J Neurosci 21, 1757-1766.

Liu, K., Kim, J., Kim, D.W., Zhang, Y.S., Bao, H., Denaxa, M., Lim, S.A., Kim, E., Liu, C., Wickersham, I.R., et al. (2017). Lhx6-positive GABA-releasing neurons of the zona incerta promote sleep. Nature 548, 582-587.

Mohammad, F., Stewart, J.C., Ott, S., Chlebkova, K., Chua, J.Y., Koh, T.W., Ho, J., and Claridge-Chang, A. (2017). Optogenetic inhibition of behavior with anion channelrhodopsins. Nat Methods 14, 271-274.

Nair-Roberts, R.G., Chatelain-Badie, S.D., Benson, E., White-Cooper, H., Bolam, J.P., and Ungless, M.A. (2008). Stereological estimates of dopaminergic, GABAergic and glutamatergic neurons in the ventral tegmental area, substantia nigra and retrorubral field in the rat. Neuroscience 152, 1024-1031.

Oishi, Y., Suzuki, Y., Takahashi, K., Yonezawa, T., Kanda, T., Takata, Y., Cherasse, Y., and Lazarus, M. (2017a). Activation of ventral tegmental area dopamine neurons

produces wakefulness through dopamine D2-like receptors in mice. *Brain structure & function* 222, 2907-2915.

Oishi, Y., Xu, Q., Wang, L., Zhang, B.J., Takahashi, K., Takata, Y., Luo, Y.J., Cherasse, Y., Schiffmann, S.N., de Kerchove d'Exaerde, A., *et al.* (2017b). Slow-wave sleep is controlled by a subset of nucleus accumbens core neurons in mice. *Nature communications* 8, 734.

Pignatelli, M., and Bonci, A. (2015). Role of Dopamine Neurons in Reward and Aversion: A Synaptic Plasticity Perspective. *Neuron* 86, 1145-1157.

Rasch, B., and Born, J. (2013). About sleep's role in memory. *Physiological reviews* 93, 681-766.

Saito, Y.C., Maejima, T., Nishitani, M., Hasegawa, E., Yanagawa, Y., Mieda, M., and Sakurai, T. (2018). Monoamines Inhibit GABAergic Neurons in Ventrolateral Preoptic Area That Make Direct Synaptic Connections to Hypothalamic Arousal Neurons. *J Neurosci* 38, 6366-6378.

Sakurai, T. (2007). The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. *Nat Rev Neurosci* 8, 171-181.

Saper, C.B., Fuller, P.M., Pedersen, N.P., Lu, J., and Scammell, T.E. (2010). Sleep State Switching. *Neuron* 68, 1023-1042.

Scammell, T.E., Arrigoni, E., and Lipton, J.O. (2017). Neural Circuitry of Wakefulness and Sleep. *Neuron* 93, 747-765.

Schmidt, M.H. (2014). The energy allocation function of sleep: A unifying theory of sleep, torpor, and continuous wakefulness. *Neuroscience & Biobehavioral Reviews* 47, 122-153.

Shank, E.J., Seitz, P.K., Bubar, M.J., Stutz, S.J., and Cunningham, K.A. (2007). Selective ablation of GABA neurons in the ventral tegmental area increases spontaneous locomotor activity. *Behavioral neuroscience* 121, 1224-1233.

Siegel, J.M. (2008). Do all animals sleep? *Trends in Neurosciences* 31, 208-213.

Tabuchi, S., Tsunematsu, T., Black, S.W., Tominaga, M., Maruyama, M., Takagi, K., Minokoshi, Y., Sakurai, T., Kilduff, T.S., and Yamanaka, A. (2014). Conditional Ablation of Orexin/Hypocretin Neurons: A New Mouse Model for the Study of Narcolepsy and Orexin System Function. *The Journal of Neuroscience* 34, 6495-6509.

Takata, Y., Oishi, Y., Zhou, X.-Z., Hasegawa, E., Takahashi, K., Cherasse, Y., Sakurai, T., and Lazarus, M. (2018). Sleep and wakefulness are controlled by ventral medial

midbrain/pons GABAergic neurons in mice. *The Journal of Neuroscience*, 0598-0518.

Tan, Kelly R., Yvon, C., Turiault, M., Mirzabekov, Julie J., Doehner, J., Labouèbe, G., Deisseroth, K., Tye, Kay M., and Lüscher, C. (2012). GABA Neurons of the VTA Drive Conditioned Place Aversion. *Neuron* 73, 1173-1183.

van Zessen, R., Phillips, Jana L., Budygin, Evgeny A., and Stuber, Garret D. (2012). Activation of VTA GABA Neurons Disrupts Reward Consumption. *Neuron* 73, 1184-1194.

Winton-Brown, T.T., Fusar-Poli, P., Ungless, M.A., and Howes, O.D. (2014). Dopaminergic basis of salience dysregulation in psychosis. *Trends Neurosci* 37, 85-94.

Wulff, K., Gatti, S., Wettstein, J.G., and Foster, R.G. (2010). Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease. *Nat Rev Neurosci* 11, 589-599.

Xie, L., Kang, H., Xu, Q., Chen, M.J., Liao, Y., Thiyagarajan, M., O'Donnell, J., Christensen, D.J., Nicholson, C., Iliff, J.J., *et al.* (2013). Sleep drives metabolite clearance from the adult brain. *Science* 342, 373-377.

Yang, S.R., Hu, Z.Z., Luo, Y.J., Zhao, Y.N., Sun, H.X., Yin, D., Wang, C.Y., Yan, Y.D., Wang, D.R., Yuan, X.S., *et al.* (2018). The rostromedial tegmental nucleus is essential for non-rapid eye movement sleep. *PLoS biology* 16, e2002909.

Yu, X., Li, W., Ma, Y., Tossell, K., Harris, J.J., Harding, E.C., Ba, W., Miracca, G., Wang, D., Li, L., *et al.* (2019). GABA and glutamate neurons in the VTA regulate sleep and wakefulness. *Nature Neuroscience* 22, 106-119.




Figure 1: VTA_{Gad67+} neurons project to multiple areas in the brain. a) Schematic of AAV injection to express Cre-inducible hrGFP in *Gad67-Cre* mice. The dotted brain map area is shown to the right. White rectangular area is shown below. b) Immunohistochemical studies showing expression of hrGFP in *Gad67+* neurons (arrowhead), but not in the nearby DA (arrow) neurons. c) Pie chart showing the percent of hrGFP expression in DA and non-DA neurons in the VTA (n = 4). d and e) Expression of hrGFP in VTA_{Gad67+} neurons and some of their projected brain areas shown. f) Table showing the comparative scoring of hrGFP signals across different brain areas. Abbreviations- DEn: dorsal endopiriform nucleus, AcbC: accumbens nucleus, core, AcbSh: accumbens

1 nucleus, shell, CPu: caudate putamen (striatum), LPO: lateral preoptic area, VP: ventral
 2 pallidum, CeA: central nucleus of the amygdala, BLA: basolateral amygdala, Xi: xiphoid
 3 thalamic nucleus, LH: lateral hypothalamic area, IMD: intermediodorsal thalamic
 4 nucleus, CM: central medial thalamic nucleus, PF: parafascicular thalamic nucleus, MM:
 5 medial mammillary nucleus, SubB: subbrachial nucleus, PAG: periaqueductal gray,
 6 Pa4: paratrochlear nucleus, VLL: ventral nucleus of the lateral lemniscus, DR: dorsal
 7 raphe nucleus, InG: intermediate gray layer of the superior colliculus, CnF: cuneiform
 8 nucleus, xscp: decussation of the superior cerebellar peduncle, and PnO: pontine
 9 reticular nucleus.




Figure 2: Chemogenetic activation of VTA_{Gad67+} neurons induced long-lasting NREM sleep. a) Schematic of Cre-inducible expression of either hM3Dq-mCherry or mCherry in VTA_{Gad67+} neurons. b) Immunohistochemical confirmation of hM3Dq-mCherry

expression in the VTA non-DA neurons. c) Time spent in each vigilance state before and after i.p. administration of either saline or CNO. Arrowhead indicates timing of injection (just before the dark period; hM3Dq: n = 6 mice; mCherry: n = 4 mice). White and grey bars above the x-axis indicate light and dark periods, respectively. d) 4 hr average time spent in each vigilance states after i.p. administration. e) Relative power of fast Fourier transformation (FFT) analysis of NREM sleep for hM3Dq-expressing saline and CNO groups before (pre: left) and after (1 hr post: middle, 4 hr post: right) i.p. administration. f) Heatmap showing a trace indicating that delta wave power activity increases after CNO administration compared to the saline control. g) Summary of the delta wave power change after saline or CNO injection. Traces in dark color indicate mean value, while lighter color indicates EEG spectrum of each mice injected with saline (black) and CNO (red). Inset shows the mean relative delta power for 4 hr after either saline or CNO administration. Data are shown as the mean \pm SEM (hM3Dq: n = 6 mice; mCherry: n = 4 mice). * $p < 0.05$, *** $p < 0.001$, (d) Two-way ANOVA followed by Tukey post hoc, (e) two-tailed paired student's t -test (n = 8 mice).




Figure 3: Optogenetic inhibition of VTA_{Gad67+} neurons induced wakefulness from NREM sleep, but not from REM sleep. a) Schematic of surgery showing *Gad67-Cre* mice expressing either ACR2-2A-mCherry or mCherry alone that were subjected to implantation of fiber optics and EEG-EMG electrodes. b) Schematic of fiber optic implantation (left). Pictures indicate position of tip of fiber optics and ACR2-2A-mCherry expression and DAT-positive neurons in the VTA. c) Schematic of protocol for light

1 stimulation in optogenetic inhibition experiments. d) Representative traces showing
 2 EEG, EEG power spectra, and EMG during optogenetic inhibition in different vigilance
 3 states (wake, NREM, and REM sleep). Vigilance states are indicated by colored bars
 4 above the EEG traces. e) Probability of vigilance state before and after light illumination
 5 in all recorded trials of ACR2-2A-mCherry or mCherry-alone expressing mice. Blue and
 6 red lines indicate mean probability of each vigilance state, ACR2-2A-mCherry (n = 6)
 7 and mCherry (n = 5). f) Light illumination in wakefulness, NREM, or REM sleep was
 8 isolated from (e). Each vigilance state lasted for at least 30 sec before light illumination
 9 was isolated. SEM is indicated as the lighter color band.




Figure 4: Optogenetic inhibition of VTA_{Gad67+} neurons induced wakefulness even under conditions of high homeostatic sleep pressure. a) Schematic of the protocol of the experiment. b) EEG, EEG power spectra, and EMG before and after optogenetic inhibition during recovery sleep after 4 hr sleep deprivation. c) Summary of the experiment in (a) showing the probability of each vigilance state before and after blue light illumination. Colored circles and lines indicate mean probability of each vigilance

- 1 state and shaded area indicates SEM (ACR2-2A-mCherry: n = 6) and mCherry alone: n
- 2 = 5).




Figure 5: *In vivo* activity recordings of VTA_{Gad67+} neurons using fiber photometry. a) Schematic of GCaMP6f expression in VTA_{Gad67+} neurons and position of fiber optics. *Gad67-Cre* mice expressing GCaMP6f were subjected to implantation of guide cannula, EEG, and EMG electrodes. PMT indicates photomultiplier tube. b)

1 Immunohistochemical studies confirmed that GCaMP6f expression was in the
2 TH-negative cells in the VTA. c) Representative traces of EEG, EEG spectra, EMG, and
3 fluorescent intensity from GCaMP6f (represented as $\Delta F/F$) in a trial having all different
4 states. Vigilance states were determined by EEG and EMG signals and indicated by
5 colored bars. d) Fluorescent intensity alterations in each trial 60 sec before and after
6 vigilance state changes. Upper panel shows the heat map of all separated transitions.
7 Middle panel represents the changes in the intensity of calcium signals represented as
8 $\Delta F/F$. Grey lines indicate average intensities in individual mice and the green line
9 indicates the mean of all mice. Lower panel indicates the average intensity separated
10 for specific vigilance states. Data are represented as mean \pm SEM. ***, $p < 0.001$; *, $p <$
11 0.05 . Two-tailed paired student's t -test ($n = 8$ mice).




Figure 6: Optogenetic activation of VTA_{Gad67+} neuronal terminals in the LH inhibited orexin neurons *in vitro*. a) AAV-mediated gene expression in *orexin-Flp; Gad67-Cre* bigenic mice. b and c) Immunohistochemical studies confirmed expression of tdTomato exclusively in orexin neurons and ChR2 in non-TH-positive neurons in the VTA. d-f) Schematic and current clamp recordings from ChR2-expressing Gad67+ neurons in the VTA in acute brain slices. Blue light stimulation of 6.8 mW/mm² increased the firing up to $674 \pm 174\%$ ($n = 5$, $p = 0.004$ vs both pre and post, one-way ANOVA followed by Tukey post hoc tests). g) Schematic of the experiments in (h). h) Firing of LH_{orexin} neurons *in vitro* and effect of activation of VTA_{Gad67+} neuronal terminals using different frequencies of blue lights (5, 10, or 20 Hz). Yellow light of 20 Hz was used as a negative control. Raster plot of each trial (upper panel) and running average of firing frequencies (lower

- 1 panel) of LH_{orexin} neurons are indicated in each rectangular box following illumination of
- 2 the brain slice through the objective lens. Two vertical red lines indicate illumination start
- 3 (left) and stop (right) timing.







Figure 7: Monosynaptic GABAergic input underlies the inhibitory effect of VTA_{Gad67+} neurons onto LH_{Orexin} neurons. a) Schematic of experiments in b-d. b) Blue light pulses (5 ms) induced post-synaptic currents in the LH_{Orexin} neurons. The thicker line indicates average traces, and the thinner line indicates responses in individual cells (n = 8). c) Summary of the experiments in b showing the amplitude of current normalized to the aCSF application. d) Delay in response from light onset. e) Schematic of the experiments in f-h. f-h) Similar data representation as in (b-e) in the presence of glutamatergic and GABAergic antagonists. i) Schematic of the experiments j-l. j) The effect of glutamatergic and GABAergic antagonists and channel blockers on blue light pulse-induced currents (n = 7). k) Summary of the experiments in (j) showing the amplitude of current normalized to aCSF (n = 6). Data are represented as mean ± SEM.



Supplementary Figure 1: Histological and electrophysiological confirmation of the expression region and function of hM3Dq in the *Gad67-Cre* mice used in Figure 2. a) Schematic of Cre-mediated expression of either hM3Dq-mCherry or mCherry alone in *Gad67-Cre* mice. b) Histological verification and reconstruction of hM3Dq-mCherry expressing areas in mice used in Figure 2. c) Schematic of patch clamp recording from hM3Dq-mCherry- or mCherry-expressing neurons in the VTA while applying CNO through the bath solution. d) Traces showing CNO-induced increases in firing of VTA_{Gad67+} neurons expressing hM3Dq-mCherry, but not of neurons expressing mCherry alone. e) Summary of experiment in (d) showing firing rate as a percent of baseline (average for 5 sec before CNO application). CNO was applied at a concentration of 30 μ M (hM3Dq: n = 8 and mCherry: n = 6, $p = 0.02$, two-tailed unpaired Student's t -test). Data are represented as mean \pm SEM.




Supplementary Figure 2: *In vitro* confirmation of ACR2-mediated optogenetic inhibition of VTA_{Gad67+} neurons. **a**) Schematic of Cre-inducible expression of either ACR2 (AAV(9)-CMV-FLEX-ACR2-2A-mCherry, 300 nl each side, 6.2×10^{12} copies/ml) or mCherry (AAV(9)-CAG-FLEX-mCherry, 300 nl each side, 1.9×10^{12} copies/ml) in VTA_{Gad67+} neurons. **b**) Immunohistochemical confirmation that ACR2-2A-mCherry-positive Gad67+ neurons are not co-expressing the dopamine transporter (DAT, expressed by DA neurons in the VTA). **c**) Schematic of recordings from ACR2-2A-mCherry or mCherry-expressing VTA_{Gad67+} neurons. **d** and **e**) Traces showing firing in a loose cell-attached mode from VTA_{Gad67+} neurons expressing either ACR2-2A-mCherry (**d**) or mCherry alone (**e**). **f**) Summary of experiment in (**d**) and (**e**), showing the firing rate as a percent of baseline (average for 5 sec before illumination). Blue light of 6.8 mW/mm² was illuminated for 5 sec (ACR2: n = 10 and mCherry: n = 7). Data are represented as mean \pm SEM.




Supplementary Figure 3: GCaMP6f-mediated recording of VTA_{Gad67+} neuronal activity in both *in vitro* and *in vivo*. a and b) Schematic of Cre-inducible expression of GCaMP6f in VTA_{Gad67+} neurons (a), and simultaneous recording of membrane potential by electrophysiology and changes in intracellular calcium concentration by calcium imaging from GCaMP6f-expressing VTA_{Gad67+} neurons (b) in brain slice using *Gad67-Cre* mice. c) Representative traces showing the correlation between the action potential frequency (middle trace) and the increase in calcium concentration intensity ($\Delta F/F$, upper trace). Action potentials were generated by injecting depolarizing current (~50 pA, lower trace) through the recording pipette at 10 Hz, 20 Hz, 50 Hz, and 100 Hz, while the $\Delta F/F$ was simultaneously measured from the same VTA_{Gad67+} neuron. i and ii shows 10 and 100 Hz current-induced action potentials. d,e) Summarized data showing

1 induced firing probability (d) and normalized $\Delta F/F$ (d) of VTA_{Gad67+} neurons from the
 2 experiment in (c) ($n = 13$, $p = 0.13$ (10 vs 20 Hz), $p = 2.5e-8$ (10 vs 50 Hz), $p = 1.0e-4$
 3 (20 vs 50 Hz), $p = 0$ (10 vs 100, 20 vs 100 and 50 vs 100 Hz), one-way ANOVA followed
 4 by post hoc Tukey test). Data are represented as mean \pm SEM. f) Traces showing 4
 5 different types of vigilance state transitions (Wake to NREM, NREM to REM, REM to
 6 Wake and NREM to wake) with corresponding EEG, EEG power spectra, EMG and
 7 calcium fluorescence ($\Delta F/F$) recorded by fiber photometry in a *Gad67-Cre* mice
 8 expressing GCaMP6f. Note that the highest fluorescence ($\Delta F/F$) was observed during
 9 the NREM sleep and the lowest during REM sleep.



Supplementary Figure 4: Histological verification of tip of fiber optics in mice used in behavioral experiments. a) Location of tip of optical fibers in all mice injected with either ACR2-2a-mCherry (n = 6, blue circles) or mCherry alone (n = 5, red circles). b) Same as in a, but for GCaMP6f-expressing mice (n = 6, green circles).



Supplementary Figure 5: Optogenetic activation of nerve terminals of VTA_{Gad67+} neurons in the LH inhibited orexin neurons in a blue-light pulse frequency-dependent manner. a) Schematic of experiment. b) Loose cell-attached recording traces from LH_{orexin} neurons while optogenetically activating VTA_{Gad67+} nerve terminals using light pulse of different wavelength and frequency. c) Summary of experiments in (b). Blue light 5 Hz (n = 7), 10 Hz (n = 8), 20 Hz (n = 9) and yellow light 20 Hz (n = 6). $p = 0.01$ (Blue 5 vs 10 Hz), $p = 3.6e-6$ (Blue 5 vs 20 Hz), $p = 0.02$ (Blue 10 vs 20 Hz), $p = 0.9$ (Blue 5 vs Yellow 20 Hz), $p = 0.004$ (Blue 10 vs Yellow 20 Hz) and $p = 1.7e-6$ (Blue 20 vs Yellow 20 Hz) one-way ANOVA followed by post hoc Tukey test). Data are represented as mean \pm SEM.

